Abstract
Based on its electrophysiologic characteristics, encainide, a new type 1 antiarrhythmic agent, was selected for a therapeutic trial in a case of refractory paroxysmal atrial fibrillation. This approach represents an attempt to manage the pathophysiologic disturbance of atrial fibrillation by selection of a drug that would be expected to have specific effects on the conduction system.
| Original language | English |
|---|---|
| Pages (from-to) | 498-502 |
| Number of pages | 5 |
| Journal | Clinical Cardiology |
| Volume | 7 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1984 |
Keywords
- antiarrhythmic therapy
- atrial fibrillation
Fingerprint
Dive into the research topics of 'The use of encainide in atrial fibrillation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver